rivastigmine has been researched along with quercetin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Finkin-Groner, E; Ginsburg, I; Lerman, L; Nudelman, A; Shalom, H; Weill, T; Weinstock, M; Yanovsky, I; Zaikin, A; Zeeli, S | 1 |
| Andrisano, V; Apperley, KYP; Bartolini, M; Baschieri, A; Basso, M; Chen, HH; De Simone, A; Guardigni, M; Keillor, JW; Kobrlova, T; Milelli, A; Montanari, S; Soukup, O; Valgimigli, L | 1 |
| Decker, M; Endres, E; Gunesch, S; Hoffmann, M; Maurice, T; Scheiner, M; Sotriffer, C; Stiller, C | 1 |
| Farias, AB; Henriques, RR; Junior, MAAL; Nogueira, TLDC; Quimas, JVF; Romeiro, NC; Santos, DC; Silva, LLD; Souza, ALF | 1 |
| Neerati, P; Palle, S | 1 |
| Hamidi, M; Hosseini, MJ; Kaboli, Z; Manjili, HK; Rostamizadeh, K; Sadighian, S | 1 |
7 other study(ies) available for rivastigmine and quercetin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Carbamates; Chickens; Cholinesterase Inhibitors; Humans; Indoles; Neurons | 2012 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; Glycogen Synthase Kinase 3 beta; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2017 |
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Disease Models, Animal; Mice; Neuroprotective Agents | 2019 |
Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Humans; Hydrazones; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Peroxidase; Picrates; Structure-Activity Relationship | 2020 |
Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.
Topics: Administration, Oral; Animals; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Esterases; Male; Microsomes, Liver; Nanoparticles; Quercetin; Rats; Rats, Wistar; Rivastigmine | 2017 |
Valine conjugated polymeric nanocarriers for targeted co-delivery of rivastigmine and quercetin in rat model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Drug Carriers; HEK293 Cells; Humans; Neuroblastoma; Polyesters; Polyethylene Glycols; Polymers; Quercetin; Rats; Rivastigmine | 2023 |